Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of ABL001 in Combination With Dasatinib, Prednisone, and Blinatumomab in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML)

Next Previous
Trial Profile

A Phase 1 Study of ABL001 in Combination With Dasatinib, Prednisone, and Blinatumomab in Patients With BCR-ABL Positive (BCR-ABL+) B-cell Acute Lymphoblastic Leukemia (B-ALL) and Chronic Myeloid Leukemia (CML)

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Asciminib (Primary) ; Blinatumomab (Primary) ; Dasatinib (Primary) ; Prednisone (Primary)
  • Indications Chronic myeloid leukaemia; Precursor B-cell lymphoblastic leukaemia-lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
  • Focus Adverse reactions

Most Recent Events

  • 04 Nov 2025 Planned End Date changed from 1 Nov 2026 to 1 Nov 2027.
  • 04 Nov 2025 Planned primary completion date changed from 1 Nov 2025 to 1 Nov 2026.
  • 12 Dec 2023 Results (n=25) assessing the hypothesis that dual ABL blockade with catalytic domain and allosteric inhibitors would be tolerable and active in BCR ABL1+ acute lymphoblastic leukemia and chronic myeloid leukemia in lymphoid blast crisis were presented at the 65th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top